Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Stocks · News reference
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Hold on Incyte, Raises Price Target to $115
Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.